Activation of plasma kinin system correlates with severe coagulation disorders in patients with ovarian hyperstimulation syndrome.
The aim of this study was to evaluate status of plasma kinin system in patients with ovarian hyperstimulation syndrome (OHSS), in order to investigate whether activation of the plasma kinin system correlates with increased blood coagulability. In the first part of the study, concentrations of plasma prekallikrein (PK) in OHSS cycles (n = 13) were monitored from the day of human chorionic gonadotrophin (HCG) administration to the mid-luteal phase, and were compared with those of control cycles (n = 17). The average value of PK in OHSS cycles began to decrease on day 8, and by day 10 was significantly lower than that of control cycles (86 +/- 6 versus 106 +/- 4%, P <0.01). The time course of changes in PK concentration correlated well with the clinical condition of OHSS patients. In the second part of the study, we obtained data from 26 patients who were hospitalized because of severe OHSS, to investigate the correlation between PK and other haemostatic markers. OHSS patients with severe PK reduction (<80% normal, n = 9) demonstrated significantly higher values of plasma thrombin-antithrombin III and plasmin-alpha2 antiplasmin, and more severe haemoconcentration, compared to those OHSS patients who had no reduction in PK (n = 17). In conclusion, our data suggest that activation of the plasma kinin system occurs specifically and occasionally in OHSS patients, and is associated with increased blood coagulability. Thus, when an OHSS patient demonstrates a low value of plasma PK, more careful management is required to prevent thromboembolic complications.
Kodama
H
H
Department of Obstetrics and Gynecology, Akita University School of Medicine, Hondo, Japan.
Takeda
S
S
Fukuda
J
J
Miya
H
H
Shimizu
Y
Y
Murata
M
M
Tanaka
T
T
D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000502:physiology*; D001779:Blood Coagulation Factors / Q000032:analysis*; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D015331:Cohort Studies; D005260:Female; D005341:Fibrinolysin / Q000032:analysis; D006400:Hematocrit; D006801:Humans; D007705:Kinins / Q000097:blood* / Q000502:physiology; D016471:Ovarian Hyperstimulation Syndrome / Q000097:blood* / Q000378:metabolism / Q000503:physiopathology; D010447:Peptide Hydrolases / Q000032:analysis; D011288:Prekallikrein / Q000032:analysis* / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors; D000979:alpha-2-Antiplasmin / Q000032:analysis
D015415:Biomarkers; D001779:Blood Coagulation Factors; D006063:Chorionic Gonadotropin; D007705:Kinins; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D011288:Prekallikrein; D010447:Peptide Hydrolases; D005341:Fibrinolysin